Rockwell Medical, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Rockwell Medical reports a significant net sales decrease in 2025, primarily due to reduced DaVita purchases, while extending its product purchase agreement with DaVita through 2026 and focusing on new customer growth.
NASDAQ
Rockwell Medical's 2024 10-K filing reveals a mixed outlook, with revenue growth offset by the impending loss of a major customer, balanced by new supply agreements and a focus on long-term growth strategies.
NASDAQ
10-K: Rockwell Medical Reports 2023 Financial Results, Highlights Strategic Growth and Market Expansion
Rockwell Medical's 2023 annual report reveals a year of strategic growth, marked by key acquisitions, new partnerships, and increased revenue, while navigating a challenging economic landscape.